|Bid||0.7226 x 1000|
|Ask||0.7400 x 900|
|Day's Range||0.7163 - 0.7599|
|52 Week Range||0.6680 - 6.0400|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.25|
CAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.
Put simply, 2021 was a great year to trade penny stocks under $1 per share — largely thanks to the Reddit meme stock phenomenon. Many may have believed elevated retail interest in day trading would cool with the recovery from the pandemic. But as we’ve seen over the past few months, that has hardly been the case. Granted, finding success in penny stocks may prove more difficult in 2022. In fact, you could argue it already is. Market participants have started to embrace a more “risk off” mindset
The biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design."